Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISAPS: rivaroxaban versus warfarin in stroke patients with antiphospholipid syndrome
2018-001735-49Phase 2Unknown
- Sponsor
- University College London
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in antiphospholipid syndrome (APS), ischemic stroke and systemic lupus erythematosus (SLE) (2 arms), sponsored by University College London. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
antiphospholipid syndrome (APS)ischemic strokesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-001735-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001735-49.